Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced 

The phase II study randomized patients to receive the combination of the two immunotherapy agents to ipilimumab alone. Researchers sought to determine the safety profile and progression-free survival (PFS) of the two arms.

Data showed a significant improvement in PFS in the combination arm versus the single-agent arm. Researchers also observed a complete remission rate in 22% of patients receiving the combination. However, autoimmune toxicities were higher in the combination arm versus the ipilimumab alone arm, and should be treated aggressively.

Videos

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Marc Ernstoff, MD

Articles

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma